ATE269848T1 - Calciumkanalblocker als antikrebsmittel - Google Patents

Calciumkanalblocker als antikrebsmittel

Info

Publication number
ATE269848T1
ATE269848T1 AT00921867T AT00921867T ATE269848T1 AT E269848 T1 ATE269848 T1 AT E269848T1 AT 00921867 T AT00921867 T AT 00921867T AT 00921867 T AT00921867 T AT 00921867T AT E269848 T1 ATE269848 T1 AT E269848T1
Authority
AT
Austria
Prior art keywords
anticancer
calcium channel
channel blockers
compounds
directed
Prior art date
Application number
AT00921867T
Other languages
English (en)
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of ATE269848T1 publication Critical patent/ATE269848T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
AT00921867T 1999-04-07 2000-04-07 Calciumkanalblocker als antikrebsmittel ATE269848T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12814399P 1999-04-07 1999-04-07
PCT/US2000/009310 WO2000059882A1 (en) 1999-04-07 2000-04-07 Anticancer calcium channel blockers

Publications (1)

Publication Number Publication Date
ATE269848T1 true ATE269848T1 (de) 2004-07-15

Family

ID=22433855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921867T ATE269848T1 (de) 1999-04-07 2000-04-07 Calciumkanalblocker als antikrebsmittel

Country Status (6)

Country Link
EP (1) EP1165508B1 (de)
JP (1) JP4932994B2 (de)
AT (1) ATE269848T1 (de)
CA (1) CA2369588C (de)
DE (1) DE60011755T2 (de)
WO (1) WO2000059882A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410871A (pt) * 2003-05-30 2006-07-04 Neuromed Tech Inc 3-aminometil-pirrolidinas como bloqueadores do canal de cálcio do tipo n
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
US20080194669A1 (en) * 2004-08-20 2008-08-14 Gray Lloyd S T Type Calcium Channel Blockers and the Treatment of Diseases
EP2073799A4 (de) * 2007-03-12 2009-08-19 Vm Discovery Inc Neuartige wirkstoffe aus kalziumionenkanalmodulatoren
PT3092901T (pt) 2007-10-05 2020-05-21 Senhwa Biosciences Inc Análogos de quinolona e respetivos métodos relacionados
EP2252608A4 (de) 2008-02-29 2012-10-03 Vm Discovery Inc Verfahren zur behandlung von schmerzsysyndrom und anderen leiden
ES2530091T3 (es) 2008-03-19 2015-02-26 Soricimed Biopharma Inc. Composiciones peptídicas para el tratamiento del cáncer por la inhibición de la actividad del canal de calcio TRPV6
EP2350002A1 (de) 2008-10-02 2011-08-03 Abbott Laboratories Neue verbindungen als kalziumkanalblocker
AR074226A1 (es) * 2008-11-26 2010-12-29 Abbott Lab Octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio, composiciones farmaceuticas que las comprenden y el uso de las mismas para el tratamiento del dolor.
US8691865B2 (en) 2008-11-26 2014-04-08 Abbvie Inc. Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
MX2012000086A (es) 2009-06-26 2012-06-12 Soricimed Biopharma Inc Peptidos derivados de soricidi y metodos para la la deteccion de canceres trpv-6 y suministro de farmaco.
MX360640B (es) 2010-03-01 2018-11-09 Tau Therapeutics Llc Star Diagnosis e imagenologia de cancer.
WO2011115813A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories Lactam acetamides as calcium channel blockers
WO2011149993A2 (en) 2010-05-25 2011-12-01 Abbott Laboratories SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
US8648074B2 (en) 2011-09-29 2014-02-11 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
US8669255B2 (en) 2011-09-29 2014-03-11 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers
MX2015007460A (es) 2012-12-12 2015-09-04 Abbvie Inc Agentes para el tratamiento del dolor y usos de los mismos.
WO2017087235A1 (en) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
TW202000195A (zh) 2018-02-15 2020-01-01 生華生物科技股份有限公司 喹啉酮類似物及其鹽、組合物及其使用方法
CN115215800B (zh) * 2021-04-21 2023-07-18 赣江中药创新中心 一种二苯并环基-环胺基醚衍生物或盐及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2454092A (en) * 1947-06-02 1948-11-16 Parke Davis & Co Benzhydryl amino ethers
US2708194A (en) * 1952-12-10 1955-05-10 Univ Michigan 2-(1-methyl) polymethyleniminylmethyl benzhydryl ethers and preparation thereof
GB833807A (en) * 1957-07-10 1960-04-27 Beecham Res Lab Benzhydryl ethers
US3732247A (en) * 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
GB1307255A (en) * 1970-09-12 1973-02-14 Pfizer Ltd Substituted basic benzhydryl ethers
FR2601366B1 (fr) * 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
FR2636946B1 (fr) * 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
GB9000301D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Piperidine & pyrrolidine derivatives
MX9100513A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
GB9020051D0 (en) * 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5981539A (en) * 1995-09-15 1999-11-09 Neurosearch A/S Piperidine compounds as calcium channel blockers
CA2204082A1 (en) * 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
JPH1135483A (ja) * 1997-05-20 1999-02-09 Nippon Kayaku Co Ltd 頻尿又は尿失禁の治療剤又は予防剤

Also Published As

Publication number Publication date
EP1165508B1 (de) 2004-06-23
WO2000059882A9 (en) 2001-11-29
JP4932994B2 (ja) 2012-05-16
WO2000059882A1 (en) 2000-10-12
JP2002541142A (ja) 2002-12-03
DE60011755T2 (de) 2005-06-30
CA2369588C (en) 2011-02-08
CA2369588A1 (en) 2000-10-12
EP1165508A1 (de) 2002-01-02
DE60011755D1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
ATE269848T1 (de) Calciumkanalblocker als antikrebsmittel
NZ506329A (en) Inhibitors of phospholipase enzymes
AU9263101A (en) Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
EP1631548A4 (de) Hemmer der akt aktivität
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
PL360373A1 (en) Non-imidazole aryloxypiperidines as h3 receptor ligands
DE60007329D1 (de) N-heterozyklische derivate als nos inhibitoren
EP1622616A4 (de) Hemmer der akt aktivität
RS20050946A (en) Pyrrolodihydroisoquinolines as pde10 inhibitors
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
GB2378948B (en) Novel compounds for modulating cell proliferation
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
MXPA05006507A (es) Inhibidores de ccxckr2 expresado en tumor humano.
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
PT1192284E (pt) Curtimenta de couro
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren
SI1244643T1 (en) Tryptase inhibitors
SI1244614T1 (en) Tryptase inhibitors
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
IL136225A0 (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties